{
    "name": "belimumab",
    "comment": "Rx",
    "other_names": [
        "Benlysta"
    ],
    "classes": [
        "Rheumatologics",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/benlysta-belimumab-999632",
    "pregnancy": {
        "common": [
            "There is a pregnancy exposure registry that evaluates pregnancy outcomes in women with lupus exposed to this therapy during pregnancy; healthcare professionals are encouraged to refer patients and pregnant women are encouraged to enroll themselves by calling 1-877-311-8972 or visiting ",
            "Data are insufficient to determine whether there is a drug-associated risk for major birth defects or miscarriage",
            "There are risks to the mother and fetus associated with SLE, including worsening of the underlying disease, premature birth, spontaneous abortion, and intrauterine growth restriction"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "Maternal lupus nephritis increases the risk of hypertension and preeclampsia/eclampsia",
                    "Passage of maternal antiphospholipid antibodies across the placenta may result in adverse neonatal outcomes, including neonatal lupus and congenital heart block",
                    "Monoclonal antibodies, such as belimumab, are actively transported across the placenta during the third trimester of pregnancy and may affect immune response in the in utero-exposed infant",
                    "Use during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Following an assessment of benefit versus risk, if prevention of pregnancy is warranted, females of reproductive potential should use effective contraception during treatment and for at least 4 months after the final treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Passage of maternal antiphospholipid antibodies across the placenta may result in adverse neonatal outcomes, including neonatal lupus and congenital heart block",
            "Monoclonal antibodies, such as belimumab, are actively transported across the placenta during the third trimester of pregnancy and may affect immune response in the in utero-exposed infant",
            "Use during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus",
            "Because maternal antibodies are excreted in human breast milk, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of breastfeeding to the infant and the importance of the drug to the mother"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Anaphylaxis to belimumab"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Serious and sometimes fatal infections reported in patients receiving immunosuppressive agents; consider risk and benefit before initiating treatment in patients with severe or chronic infections; consider interrupting therapy in patients who develop a new infection during therapy and monitor patients closely",
                "Impact on development of malignancies is unknown; as with other immunomodulating agents, mechanism of action of belimumab could increase the risk for developing malignancies; consider individual benefit-risk in patients with known risk factors for development or reoccurrence of malignancy prior to prescribing this medication; in patients who develop malignancies, consider risk and benefit of continued treatment",
                "Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, reported in patients with SLE receiving immunosuppressants; risk factors for PML include treatment with immunosuppressant therapies and impairment of immune function; consider diagnosis of PML in any patient presenting with new-onset or deteriorating neurological signs and symptoms and consult with a neurologist or other appropriate specialist as clinically indicated; in patients with confirmed PML, consider stopping therapy"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Acute hypersensitivity reactions, including anaphylaxis and death, reported; events generally occurred within hours of infusion; however, they may occur later; non-acute hypersensitivity reactions including rash, nausea, fatigue, myalgia, headache, and facial edema reported and typically occurred up to a week following the most recent infusion",
                        "Hypersensitivity, including serious reactions, has occurred in patients who have previously tolerated infusions of the drug; limited data suggest that patients with a history of multiple drug allergies or significant hypersensitivity may be at increased risk",
                        "Therapy should be administered by healthcare providers prepared to manage anaphylaxis; in the event of a serious reaction, discontinue treatment immediately and administer appropriate medical therapy; monitor patients during infusion and for an appropriate period of time after intravenous administration of the drug",
                        "Consider administering premedication as prophylaxis prior to intravenous dosing; Inform patients receiving the drug of the signs and symptoms of hypersensitivity reactions and instruct them to seek immediate medical care should a reaction occur"
                    ]
                },
                {
                    "type": "Infusion reactions",
                    "description": [
                        "Serious infusion reactions (excluding hypersensitivity reactions) reported, including bradycardia, myalgia, headache, rash, urticaria, and hypotension; most common reactions included headache, nausea, and skin reactions; consider administering premedication as prophylaxis prior to intravenous dosing",
                        "For intravenous use, therapy should be administered by healthcare providers prepared to manage infusion reactions; infusion rate may be slowed or interrupted if patient develops a reaction; monitor during and for an appropriate period of time after infusion",
                        "Healthcare providers should be aware of risk of hypersensitivity reactions, which may present as infusion reactions, and monitor patients closely; instruct patients to seek immediate medical care should a reaction occur"
                    ]
                },
                {
                    "type": "Depression and suicidality",
                    "description": [
                        "In clinical trials, psychiatric events were associated with IV administration in SLE patients",
                        "Before treatment, assess risk of depression and suicide considering the patientâ€™s medical history and current psychiatric status",
                        "Continue to monitor during treatment",
                        "Instruct patients to contact healthcare provider if new or worsening depression arises, suicidal thoughts or behavior, or other mood changes; assess risk and benefit of continued therapy for patients who develop such symptoms",
                        "Consider risk and benefit of continued treatment for patients who develop symptoms of depression or suicidality"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Immunizations",
                        "Do not administer live vaccines 30 days before or concurrently with belimumab",
                        "May decrease response to immunizations",
                        "Other biologic therapies",
                        "Coadministration not recommended",
                        "Not studied in combination with other biologic therapies (eg, B-cell targeted therapies) ",
                        "Concomitant use with rituximab increased incidence of serious infections and post-injection systemic reactions observed"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "anthrax vaccine adsorbed",
            "description": {
                "common": "belimumab decreases effects of anthrax vaccine adsorbed by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "belimumab decreases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "diphtheria & tetanus toxoids",
            "description": {
                "common": "belimumab decreases effects of diphtheria & tetanus toxoids by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "diphtheria & tetanus toxoids/ acellular pertussis vaccine",
            "description": {
                "common": "belimumab decreases effects of diphtheria & tetanus toxoids/ acellular pertussis vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine",
            "description": {
                "common": "belimumab decreases effects of diphtheria & tetanus toxoids/acellular pertussis/poliovirus, inactivated vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "hepatitis A vaccine inactivated",
            "description": {
                "common": "belimumab decreases effects of hepatitis A vaccine inactivated by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "hepatitis a/b vaccine",
            "description": {
                "common": "belimumab decreases effects of hepatitis a/b vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "hepatitis b vaccine",
            "description": {
                "common": "belimumab decreases effects of hepatitis b vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "influenza A (H5N1) vaccine",
            "description": {
                "common": "belimumab decreases effects of influenza A (H5N1) vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "influenza virus vaccine (H5N1), adjuvanted",
            "description": {
                "common": "belimumab decreases effects of influenza virus vaccine (H5N1), adjuvanted by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "influenza virus vaccine quadrivalent, cell-cultured",
            "description": {
                "common": "belimumab decreases effects of influenza virus vaccine quadrivalent, cell-cultured by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "belimumab decreases effects of influenza virus vaccine quadrivalent, intranasal by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "Japanese encephalitis virus vaccine",
            "description": {
                "common": "belimumab decreases effects of Japanese encephalitis virus vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "belimumab decreases effects of measles (rubeola) vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "belimumab decreases effects of measles mumps and rubella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "belimumab decreases effects of measles, mumps, rubella and varicella vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "meningococcal A C Y and W-135 polysaccharide vaccine combined",
            "description": {
                "common": "belimumab decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pneumococcal vaccine 13-valent",
            "description": {
                "common": "belimumab decreases effects of pneumococcal vaccine 13-valent by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pneumococcal vaccine heptavalent",
            "description": {
                "common": "belimumab decreases effects of pneumococcal vaccine heptavalent by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pneumococcal vaccine polyvalent",
            "description": {
                "common": "belimumab decreases effects of pneumococcal vaccine polyvalent by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rabies vaccine",
            "description": {
                "common": "belimumab decreases effects of rabies vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rabies vaccine chick embryo cell derived",
            "description": {
                "common": "belimumab decreases effects of rabies vaccine chick embryo cell derived by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "belimumab decreases effects of rotavirus oral vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "belimumab decreases effects of rubella vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "belimumab decreases effects of smallpox (vaccinia) vaccine, live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tetanus toxoid adsorbed or fluid",
            "description": {
                "common": "belimumab decreases effects of tetanus toxoid adsorbed or fluid by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "travelers diarrhea and cholera vaccine inactivated",
            "description": {
                "common": "belimumab decreases effects of travelers diarrhea and cholera vaccine inactivated by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tuberculin purified protein derivative",
            "description": {
                "common": "belimumab decreases effects of tuberculin purified protein derivative by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "typhoid polysaccharide vaccine",
            "description": {
                "common": "belimumab decreases effects of typhoid polysaccharide vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "belimumab decreases effects of typhoid vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "belimumab, upadacitinib.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "belimumab decreases effects of varicella virus vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "belimumab decreases effects of yellow fever vaccine by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "belimumab decreases effects of zoster vaccine live by immunosuppressive effects; risk of infection. Contraindicated. Do not administer live vaccines 30 days before or concurrently with belimumab."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "belimumab decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "human papillomavirus vaccine, nonavalent",
            "description": {
                "common": "belimumab decreases effects of human papillomavirus vaccine, nonavalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "human papillomavirus vaccine, quadrivalent",
            "description": {
                "common": "belimumab decreases effects of human papillomavirus vaccine, quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids (used in greater than physiologic doses), may reduce the immune responses to vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "belimumab decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "belimumab decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept and belimumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "denosumab",
            "description": {
                "common": "belimumab, denosumab. Other (see comment). Use Caution/Monitor. \nComment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "belimumab increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "hydroxyurea, belimumab. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of infection."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, belimumab.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, recombinant",
            "description": {
                "common": "belimumab decreases effects of influenza virus vaccine quadrivalent, recombinant by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine trivalent, recombinant",
            "description": {
                "common": "belimumab decreases effects of influenza virus vaccine trivalent, recombinant by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine and belimumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal group B vaccine",
            "description": {
                "common": "belimumab decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, belimumab.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olaparib",
            "description": {
                "common": "belimumab and olaparib both increase  pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents,  may potentiate and prolongate the myelosuppressive toxicity. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin and belimumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Use of oxaliplatin with concomitant immunosuppressants or with impaired immune systems may increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "poliovirus vaccine inactivated",
            "description": {
                "common": "belimumab decreases effects of poliovirus vaccine inactivated by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Patients vaccinated within a 14-day period before starting or during immunosuppressive therapy should be revaccinated =3 months after therapy is discontinued if immune competence has been restored. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "belimumab decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, belimumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, belimumab.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine recombinant",
            "description": {
                "common": "belimumab decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "15"
        },
        {
            "name": "Diarrhea",
            "percent": "12"
        },
        {
            "name": "Pyrexia",
            "percent": "10"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "9"
        },
        {
            "name": "Bronchitis",
            "percent": "9"
        },
        {
            "name": "Insomnia",
            "percent": "7"
        },
        {
            "name": "Pain in extremity",
            "percent": "6"
        },
        {
            "name": "Depression",
            "percent": "5"
        },
        {
            "name": "Migraine",
            "percent": "5"
        },
        {
            "name": "Pharyngitis",
            "percent": "5"
        },
        {
            "name": "Cystitis",
            "percent": "4"
        },
        {
            "name": "Leukopenia",
            "percent": "4"
        },
        {
            "name": "Gastroenteritis viral",
            "percent": "3"
        },
        {
            "name": "Serious infections",
            "percent": "4.1"
        },
        {
            "name": "Depression",
            "percent": "2.7"
        },
        {
            "name": "related events",
            "percent": "1.3"
        },
        {
            "name": "Suicidal ideation",
            "percent": "0.5"
        },
        {
            "name": "Fatal infections",
            "percent": "0.2"
        },
        {
            "name": "Serious psychiatric events",
            "percent": null
        }
    ]
}